[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"muscle-spasticity\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:muscle-spasticity":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,59,88,119,144,169,199],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":55,"locationsCount":58},"100602032","ultrasonographic-assessment-of-muscle-morphology-function-and-clinical-findings-in-spastic-cerebral-palsy-100602032",false,"NCT07118228","Ultrasonographic Assessment of Muscle Morphology, Function, and Clinical Findings in Spastic Cerebral Palsy","Evaluation of the Relationship Between Ultrasonographic Muscle Morphology, Functional Properties, and Clinical Parameters in Children With Spastic Cerebral Palsy","US-sCP","Inclusion Criteria:\n\n* Diagnosis of spastic cerebral palsy (SCP) according to the criteria defined by Rosenbaum et al. (2007)\n* Age between 4 and 18 years\n* Gross Motor Function Classification System (GMFCS) Level I, II, or III\n* Manual Ability Classification System (MACS) Level I, II, III, or IV\n\nExclusion Criteria:\n\n* Non-spastic types of cerebral palsy (e.g., dyskinetic, ataxic)\n* Diagnosis of neuromuscular disorders other than cerebral palsy (e.g., hereditary neuropathy, myopathy)\n* Presence of muscle contractures or fixed deformities in the limbs selected for ultrasound and clinical assessment\n* Cognitive or behavioral impairments that prevent cooperation during ultrasound or clinical evaluation\n* Botulinum toxin-A (BoNT-A) injection applied to the target muscles within the last 6 months\n* Current treatment with oral or intrathecal antispastic medications\n* History of orthopedic surgery or selective dorsal rhizotomy involving the target muscles\n* Acute infection, febrile illness, or severe systemic disease (e.g., advanced heart failure, respiratory insufficiency) that may compromise the safety of assessments","ALL","4 Years","18 Years",{"count":21,"type":22},36,"ESTIMATED","OBSERVATIONAL","This study focuses on children with spastic cerebral palsy and aims to examine how muscle morphology and tissue characteristics, as assessed by ultrasound, may relate to functional motor abilities. It is designed as a prospective, cross-sectional, observational study. Planned ultrasound-based assessments include parameters such as muscle thickness, pennation angle, fascicle length, echo intensity, tissue stiffness (via shear wave elastography), and microvascular flow (via superb microvascular imaging). These measurements are intended to be compared with standard clinical evaluations, including the GMFCS, GMFM-66, MAS, MACS, and Tardieu Scale. The study seeks to contribute to a better understanding of the relationship between muscle architecture and functional outcomes, with the goal of generating insights that may inform individualized rehabilitation planning.",[26,27,28],"Muscle Spasticity","Gait Disorders, Neurologic","Cerebral Palsy, Spastic",[30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45],"Spastic Cerebral Palsy","Muscle Morphology","Shear Wave Elastography","Muscle Architecture","Superb Microvascular Imaging","Muscle Stiffness","Pennation Angle","Fascicle Length","Intramuscular Vascularity","Echo Intensity","GMFM-66","Gross Motor Function","Muscle Morphology and Function","Ultrasound Imaging","Ultrasound Imaging of Spastic Muscle","Functional Assessment","RECRUITING","2026-01-30",{"date":49,"type":50},"2026-02-03","ACTUAL",{"date":52,"type":50},"2025-12-15",{"date":54,"type":22},"2026-06-30",{"name":56,"class":57},"Kocaeli University","OTHER",1,{"id":60,"slug":61,"hasResults":11,"nctId":62,"briefTitle":63,"officialTitle":63,"acronym":4,"eligibilityCriteria":64,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":65,"enrollmentInfo":66,"targetDuration":4,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":75,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":58},"100293157","exoskeleton-and-spinal-cord-stimulation-for-sci-100293157","NCT03096197","Exoskeleton and Spinal Cord Stimulation for SCI","Inclusion Criteria:\n\nIn order to be eligible to participate in this study a participant must:\n\n* be a non-walker with an SCI greater than 6 years post injury;\n* have a lower extremity motor score greater or equal to 16 as measured by the International Standards for Neurological Classification of SCI exam;\n* be between the ages of 18-65 years old;\n* have a spinal cord injury at a neurological level of injury as determined by study staff between C5-T-10;\n* be wheelchair reliant 100% of the time;\n* have knee bone mineral density great than .5755gm\u002Fcm2 as determined by study staff;\n\nExclusion Criteria:\n\n* have a history of broken or fractured bones.\n* have a history of bone trauma or bone disease.","65 Years",{"count":67,"type":22},24,"INTERVENTIONAL",[70],"NA","The overall aim of this project is to assess the effect of combining transcutaneous lumbosacral stimulation (TLS) during Exoskeleton Assisted Walking (EAW) compared to EAW alone without stimulation on walking recovery.",[73,74,26],"Spinal Cord Injury","Ambulation Difficulty",[76,77,78],"Spinal Cord injury (SCI)","Transcutaneous lumbosacral stimulation (TLS)","Exoskeleton-Assisted Walking (EAW)","2026-01-12",{"date":81,"type":50},"2026-01-14",{"date":83,"type":50},"2017-03-30",{"date":85,"type":22},"2029-09",{"name":87,"class":57},"Kessler Foundation",{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":4,"eligibilityCriteria":94,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":95,"targetDuration":4,"studyType":68,"phases":97,"briefSummary":98,"conditions":99,"keywords":102,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":58},"100572419","comparing-upper-limb-surgery-and-botulinum-toxin-for-spasticity-a-paired-design-study-100572419","NCT06733025","Comparing Upper Limb Surgery and Botulinum Toxin for Spasticity: A Paired Design Study","The Effectiveness of Spasticity-correcting Upper Limb Surgery Versus Botulinum Toxin Injections in Patients With Upper Limb Spasticity: an Experimental Study With Paired Design","Inclusion Criteria:\n\n1. 18 years or above\n2. Problematic spasticity, characterised by a velocity-dependent increase in tonic stretch reflexes or intermittent or sustained involuntary muscle activity in the UL after stroke, TBI, or SCI\n3. Patients treated at least 6 months after the injury event\n4. Ongoing BoNT treatment in the UL\n5. A minimum of 3 months passed since the last BoNT injection\n6. At least two muscles in the hand and wrist were considered for treatment\n7. For the BoNT group, a community occupational or physical therapist was assigned for post BoNT treatment\n8. For the surgery group, medically stable to undergo surgery\n9. No other severe UL injuries affecting the functional level\n\nExclusion Criteria:\n\n\\-",{"count":96,"type":22},30,[70],"Spasticity is a common complication following central nervous system injuries. Left untreated, spasticity can lead to various complications, hindering activities of daily living and diminishing independence. Spasticity affecting the hand is particularly debilitating because it prevents prehension and grasp, which are critical factors for the ability to perform activities of daily living independently. Spasticity is described as one of the prominent secondary conditions in individuals with various disabilities.\n\nWhile Botulinum toxin(BoNT) injections are widely used for focal spasticity, surgical interventions remain underutilized despite promising long-term outcomes. Center for Advanced Reconstruction of Extremities(C.A.R.E), at the hand surgery department at Sahlgrenska University hospital in Gothenburg, Sweden is a multiprofessional team and advocates a stratified surgical algorithm based on residual motor function, aiming to optimize patient outcomes.\n\nThis open-label, non-randomized, paired study aims to compare the efficacy of spasticity-correcting upper limb surgery with BoNT injections in improving body function, activity, and participation in patients with upper limb spasticity. A total of 30 patients will undergo both interventions sequentially, allowing for within-patient comparisons. The sample size calculation is based on prior studies.\n\nAll patients with ongoing BoNT treatment who get referral to C.A.R.E and seem eligible for the study will be informed about the study and enrolment procedure. Eligible participants will undergo both treatments sequentially, with outcome assessments conducted before and after each intervention. The treatments will follow routine clinical care.\n\nThe primary outcome measure, Modified Ashworth Scale, will assess spasticity severity. Secondary outcomes will include measures of functional and activity changes specific to each treatment regimen.\n\nThis study aims to provide valuable insights into the comparative effectiveness of spasticity interventions, guiding treatment decisions for patients with upper limb spasticity.",[26,73,100,101],"Stroke","Traumatic Brain Injuries",[103,104,105,106,107,108],"Muscle spasticity","spinal cord injury","stroke","traumatic brain injuries","tendon lengthening","Botulinum toxin injection","2025-09-16",{"date":111,"type":50},"2025-09-17",{"date":113,"type":50},"2025-01-07",{"date":115,"type":22},"2029-06-29",{"name":117,"class":118},"Vastra Gotaland Region","OTHER_GOV",{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":126,"targetDuration":4,"studyType":68,"phases":128,"briefSummary":129,"conditions":130,"keywords":131,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":58},"100567945","sirs-eswt-trial-shoulder-internal-rotator-spasticity-trial-treated-with-extracorporeal-shock-wave-therapy-trial-100567945","NCT06674785","SIRS-ESWT Trial: Shoulder Internal Rotator Spasticity Trial Treated With Extracorporeal Shock Wave Therapy Trial","Effects of Extracorporeal Shock Wave Therapy on Shoulder Internal Rotator Spasticity in Post-Stroke Patients: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients aged 18 years or older with unilateral cerebral stroke.\n* Restricted passive external rotation of the spastic shoulder by more than 20 degrees.\n* A Modified Ashworth Scale score of 1 or higher for shoulder internal rotator spasticity.\n* Stable medical condition and vital signs.\n* Clear consciousness, able to follow instructions.\n\nExclusion Criteria:\n\n* History of two or more strokes, traumatic brain injury, brain tumors, or other cerebral disorders.\n* Coexisting central nervous system disorders (e.g., spinal cord injury, Parkinson's disease) or other musculoskeletal conditions affecting muscle tone assessment.\n* Ineligibility for shock wave intervention due to malignancies, coagulation disorders, localized infections, or presence of a pacemaker.\n* Prior shock wave intervention or botulinum toxin injection for post-stroke spasticity within the past three months.\n* Inability to participate in interventions or functional assessments due to cognitive, consciousness, or language impairments.",{"count":127,"type":22},40,[70],"Extracorporeal shock wave therapy (ESWT) has shown potential in reducing post-stroke limb spasticity. This study aims to evaluate the efficacy of focused ESWT on shoulder internal rotator spasticity in post-stroke patients.",[100,26],[105,132,133,134],"spasticity","shock wave","shoulder","2025-07-27",{"date":137,"type":50},"2025-07-29",{"date":139,"type":50},"2025-07-23",{"date":141,"type":22},"2027-12-31",{"name":143,"class":57},"National Taiwan University Hospital",{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":148,"acronym":4,"eligibilityCriteria":149,"healthyVolunteers":11,"sex":17,"minAge":150,"maxAge":151,"enrollmentInfo":152,"targetDuration":4,"studyType":68,"phases":154,"briefSummary":155,"conditions":156,"keywords":4,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":165,"leadSponsor":167,"locationsCount":58},"100585423","effect-of-diving-and-aquatic-exercises-on-muscle-spasticity-and-motor-function-in-children-with-spastic-cerebral-palsy-100585423","NCT06902168","Effect of Diving and Aquatic Exercises on Muscle Spasticity and Motor Function in Children With Spastic Cerebral Palsy","Inclusion Criteria:\n\n* Age from 2 to 5 years.\n* Both sexes.\n* Children diagnosed with spastic cerebral palsy, categorized according to the Gross motor function classification system (GMFCS) levels IV, V.\n\nExclusion Criteria:\n\n* Botulinum toxin treatment or surgery in the preceding three months.\n* Botox injections before or during the application of the program.\n* Dorsal rhizotomy.","2 Years","5 Years",{"count":153,"type":22},37,[70],"This study aims to evaluate the effect of diving and aquatic exercises on muscle spasticity and motor function in children with spastic cerebral palsy.",[157,158,26,159,160,30],"Diving","Aquatic","Motor Function","Children","2025-03-29",{"date":163,"type":50},"2025-04-01",{"date":161,"type":50},{"date":166,"type":22},"2025-08-01",{"name":168,"class":57},"Benha University",{"id":170,"slug":171,"hasResults":11,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":175,"eligibilityCriteria":176,"healthyVolunteers":177,"sex":17,"minAge":150,"maxAge":19,"enrollmentInfo":178,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":180,"conditions":181,"keywords":185,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":58},"100478150","how-are-the-muscles-affected-in-cerebral-palsy-a-study-of-muscle-biopsies-taken-during-orthopaedic-surgery-100478150","NCT05506228","How Are the Muscles Affected in Cerebral Palsy? A Study of Muscle Biopsies Taken During Orthopaedic Surgery.","How Are the Muscles Affected in Cerebral Palsy? A Study of Muscle Biopsies Taken During Orthopaedic Surgery of Children With Cerebral Palsy and Typically Developed Children (Control).","CPTDBiopsy","Inclusion Criteria:\n\n* Children and adolescents undergoing clinically needed orthopaedic surgery\n* with Cerebral Palsy or Acquired Brain Injury\n* Typically developed children and adolescents (control)\n\nExclusion Criteria:\n\n* for CP\u002FABI: Progressive neurological disease, other metabolic or muscle disease\n* for TD (Control): Cerebral Palsy, Acquired Brain injury, other metabolic or muscle diseases",true,{"count":179,"type":22},150,"* Cerebral palsy (CP) is a motor disorder caused by an injury to the immature brain. Even though the brain damage does not change, children with CP will have progressively weaker, shorter and stiffer muscles that will lead to contractures, bony deformations, difficulty to walk and impaired manual ability. An acquired brain injury (ABI) later during childhood, such as after a stroke or an injury, will result in similar muscle changes, and will therefore also be included in this study. For simplicity, these participants will in this text be referred to as having CP.\n* The mechanism for the muscle changes is still unknown. Contractures and the risk for the hips to even dislocate is now treated by tendon lengthening, muscle release and bony surgery. During these surgeries muscle biopsies, tendon biopsies and blood samples will be taken and compared with samples from typically developed (TD) children being operated for fractures, knee injuries, and deformities. The specimens will be explored regarding inflammatory markers, signaling for muscle growth, signaling for connective tissue growth and muscle and tendon pathology. In blood samples, plasma and serum, e.g. pro-inflammatory cytokines and the cytoprotective polypeptide humanin will measured, and will be correlated to the amount humanin found in muscle. With this compound information the mechanism of contracture formation may be found, and hopefully give ideas for treatment that will protect muscle and joint health, including prevention of hip dislocation and general health.\n* The results will be correlated to the degree of contracture of the joint and the severity of the CP (GMFCS I-V, MACS I-V).\n* By comparing muscle biopsies from the upper limb with muscle biopsies from the lower limb, muscles that are used in more or less automated gait will be compared to muscles in the upper limb that are used more voluntarily and irregularly.\n* Muscles that flex a joint, often contracted, will be compared with extensor muscles from the same patient. Fascia, aponeurosis and tendon will also be sampled when easily attainable.",[182,183,184,26],"Cerebral Palsy","Muscle","Muscle Contracture",[182,186,187,188,189],"Upper Limb","Lower Limb","Muscle Biopsy","Plasma","2022-08-16",{"date":192,"type":50},"2022-08-18",{"date":194,"type":50},"2002-01-15",{"date":196,"type":22},"2033-12-15",{"name":198,"class":118},"Eva Ponten",{"id":200,"slug":201,"hasResults":11,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":205,"eligibilityCriteria":206,"healthyVolunteers":11,"sex":17,"minAge":150,"maxAge":19,"enrollmentInfo":207,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":209,"conditions":210,"keywords":212,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":58},"100477487","the-muscle-in-children-with-cerebral-palsy---longitudinal-exploration-of-microscopic-muscle-structure-100477487","NCT05497609","The Muscle in Children With Cerebral Palsy - Longitudinal Exploration of Microscopic Muscle Structure.","The Muscle in Children Cerebral Palsy - Longitudinal Exploration of Microscopic Muscle Structure in Gastrocnemius and Biceps Brachii During Two Years of Care as Usual, Including Training With Botulinum Toxin Injections as Adjuvant Therapy.","CPBiopsyBTX","Inclusion Criteria:\n\n* Cerebral Palsy, Aquired Brain Injury\n\nExclusion Criteria:\n\n* Progressive neural disease",{"count":208,"type":22},50,"Cerebral palsy (CP) is a motor impairment due to a brain malformation or a brain lesion before the age of two. Spasticity, hypertonus in flexor muscles, dyscoordination and an impaired sensorimotor control are cardinal symptoms. The brain lesion is non-progressive, but the flexor muscles of the limbs will during adolescence become relatively shorter and shorter (contracted), forcing the joints into a progressively flexed position. This will worsen the positions of already paretic and malfunctioning arms and legs. Due to bending forces across the joints, bony malformations will occur, worsening the function even further. Since about 25 years a combination treatment with intramuscular botulinum toxin injections, braces and training has had a tremendous and increasing popularity, although lasting long-term clinical advantage is not yet proven.\n\nMuscle morphology of the biceps brachii and the gastrocnemius muscles:\n\n* The hypothesis is that care as usual, i.e. training and splinting sessions with botulinum toxin as adjuvant treatment, will reduce (normalize) the expression of the fast fatigable myosin heavy chain MyHC IIx and increase the expression of developmental myosin, as a possible sign of growth. As the biceps in the arm is used irregularly and voluntarily, and the gastrocnemius is activated during automated gait, the adaptations of those muscles will be different. Methods: Baseline muscle biopsies: Percutaneous biopsies are taken just before the first intramuscular botulinum toxin injection is given. The doses and the intervals for the botulinum toxin treatment will follow clinical routines. Biopsies 4-6 months, 12 months and 24 months after the first botulinum toxin injection: The exact same procedure as above will be performed, but the biopsies will be taken 2 cm distant, medial or lateral, from previous biopsy sites\n* Significance:. More knowledge is warranted regarding the actual molecular process in the muscle leading to a contracture, and its relation to the constant communication with the injured central nervous system. This study will give answers that could result in new, early prophylactic treatment of joint movement restrictions and motor impairment in children with CP.",[182,211,26],"Muscle Contraction",[182,186,187,188,213],"Botulinum Toxin Type A","2022-08-09",{"date":216,"type":50},"2022-08-11",{"date":218,"type":50},"2006-01-15",{"date":220,"type":22},"2027-12-15",{"name":198,"class":118}]